Xiaoran Liu
Key Laboratory Of Carcinogenesis And Translational Research
Beijing, China
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Extracellular vesicle miRNA detection based on membrane fusion and nucleic acid nanostructures.
Journal: Biosensors & bioelectronics
Published: February 21, 2025
Comprehensive Analysis of Oncogenic Somatic Alterations of Mismatch Repair Gene in Breast Cancer Patients.
Journal: Bioengineering (Basel, Switzerland)
Published: February 18, 2025
Anlotinib in combination with metronomic chemotherapy in HER2-negative metastatic breast cancer: an observational and retrospective study.
Journal: BMC cancer
Published: October 22, 2024
HER2 status results in an unstable switch from primary to recurrent breast cancer.
Journal: Neoplasma
Published: February 29, 2024
Trastuzumab Biosimilar (HLX02), Pertuzumab Plus Chemotherapy in Patients with HER2-Positive Metastatic Breast Cancer after Progression of Trastuzumab: A Prospective, Phase II Study.
Journal: Cancer research and treatment
Published: October 20, 2023
Variant allele frequency in circulating tumor DNA correlated with tumor disease burden and predicted outcomes in patients with advanced breast cancer.
Journal: Breast cancer research and treatment
Published: October 10, 2023
Long-term Outcome Analysis of Pyrotinib in Patients With HER2-Positive Metastatic Breast Cancer and Brain Metastasis: A Real-World Study.
Journal: The oncologist
Published: June 07, 2023
Endocrine therapy plus HER2-targeted therapy, another favorable option for HR+/HER2+ advanced breast cancer patients.
Journal: Therapeutic advances in medical oncology
Published: May 08, 2023
Persistence of peripheral CD8 + CD28- T cells indicates a favourable outcome and tumour immunity in first-line HER2-positive metastatic breast cancer.
Journal: British journal of cancer
Published: March 17, 2023
Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients.
Journal: Frontiers in oncology
Published: January 27, 2023
Pegylated liposomal doxorubicin (Duomeisu®) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study.
Journal: Breast cancer research and treatment
Published: December 10, 2022
Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting.
Journal: Frontiers in oncology
Published: October 21, 2022
Last Updated: 09/26/2026